Liver Diseases  >>  codrituzumab (RG7686)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
codrituzumab (RG7686) / Roche
NCT00746317: A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Completed
1
27
US
GC33
Chugai Pharmaceutical
Advanced or Metastatic HCC
10/10
10/12
NCT00976170: Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Completed
1
42
US, RoW
GC33(RO5137382), Sorafenib
Chugai Pharmaceutical, Hoffmann-La Roche
Hepatocellular Carcinoma
07/13
09/14

Download Options